|
|
NGB |
neuroglobin |
- Intracellular oxygen transport
|
|
|
|
|
NHERF1 |
NHERF family PDZ scaffold protein 1 |
|
|
- Nephrolithiasis/osteoporosis, hypophosphatemic
|
|
|
NHERF2 |
NHERF family PDZ scaffold protein 2 |
|
|
|
|
|
NOP56 |
NOP56 ribonucleoprotein |
- Association of TriC/CCT with target proteins during biosynthesis
- rRNA modification in the nucleus and cytosol
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
- Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
|
|
|
NOP58 |
NOP58 ribonucleoprotein |
- SUMOylation of RNA binding proteins
- rRNA modification in the nucleus and cytosol
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
|
|
|
NPM3 |
nucleophosmin/nucleoplasmin 3 |
|
|
|
|
|
NUMB |
NUMB endocytic adaptor protein |
- Activated NOTCH1 Transmits Signal to the Nucleus
- Recycling pathway of L1
- Degradation of GLI1 by the proteasome
- Hedgehog 'on' state
- Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
|
|
|
|
|
OSGIN1 |
oxidative stress induced growth inhibitor 1 |
|
|
|
|
|
PBK |
PDZ binding kinase |
|
|
|
|
|
PBRM1 |
polybromo 1 |
- RMTs methylate histone arginines
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Formation of the polybromo-BAF (pBAF) complex
|
|
|
|
|
PCNA |
proliferating cell nuclear antigen |
- Translesion synthesis by REV1
- Recognition of DNA damage by PCNA-containing replication complex
- Translesion Synthesis by POLH
- Transcription of E2F targets under negative control by DREAM complex
- Polymerase switching on the C-strand of the telomere
- Processive synthesis on the C-strand of the telomere
- Telomere C-strand (Lagging Strand) Synthesis
- Removal of the Flap Intermediate from the C-strand
- SUMOylation of DNA replication proteins
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- PCNA-Dependent Long Patch Base Excision Repair
- Translesion synthesis by POLK
- Translesion synthesis by POLI
- Termination of translesion DNA synthesis
- HDR through Homologous Recombination (HRR)
- Gap-filling DNA repair synthesis and ligation in GG-NER
- Dual Incision in GG-NER
- Dual incision in TC-NER
- Gap-filling DNA repair synthesis and ligation in TC-NER
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Polymerase switching
- Removal of the Flap Intermediate
- Processive synthesis on the lagging strand
- G1/S-Specific Transcription
- E3 ubiquitin ligases ubiquitinate target proteins
|
- Liothyronine
- Acetylsalicylic acid
|
|
|
|
PDGFRB |
platelet derived growth factor receptor beta |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Becaplermin
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- XL999
- XL820
- Pazopanib
- Midostaurin
- Regorafenib
- Nintedanib
- Polaprezinc
- Trapidil
- Foreskin fibroblast (neonatal)
- Tivozanib
- Fostamatinib
- Erdafitinib
- Pexidartinib
- Ripretinib
- Pralsetinib
|
|
|
|
PELO |
pelota mRNA surveillance and ribosome rescue factor |
- PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA
|
|
|
|
|
PELP1 |
proline, glutamate and leucine rich protein 1 |
- Major pathway of rRNA processing in the nucleolus and cytosol
- PTK6 Expression
|
|
|
|
|
PHB1 |
prohibitin 1 |
- RAF activation
- Signaling by moderate kinase activity BRAF mutants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Processing of SMDT1
- Signaling downstream of RAS mutants
|
- Rocaglamide
- Didesmethylrocaglamide
|
|
|
|
PHB2 |
prohibitin 2 |
- Processing of SMDT1
- Cellular response to mitochondrial stress
|
- Capsaicin
- Rocaglamide
- Didesmethylrocaglamide
|
|
|
|
PICK1 |
protein interacting with PRKCA 1 |
- Cell surface interactions at the vascular wall
- Trafficking of GluR2-containing AMPA receptors
|
|
|
|
|
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK in cancer
- Signaling by LTK
- Co-stimulation by ICOS
|
- SF1126
- Enzastaurin
- Wortmannin
|
|
|
|
PKM |
pyruvate kinase M1/2 |
- Neutrophil degranulation
- Negative Regulation of CDH1 Gene Transcription
|
- Pyruvic acid
- L-Phospholactate
- 2-Phosphoglycolic Acid
- 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
- 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
- 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
- Indoprofen
- Copper
- Polydatin
- Artenimol
|
|
|
|
PLEC |
plectin |
- Assembly of collagen fibrils and other multimeric structures
- Caspase-mediated cleavage of cytoskeletal proteins
- Type I hemidesmosome assembly
|
|
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Epidermolysis bullosa, hemidesmosomal, including: Epidermolysis bullosa, generalized atrophic benign (GABEB); Epidermolysis bullosa simplex with pyloric atresia (EBS-PA); Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
|